Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Srikala Sridhar

Neoadjuvant Chemotherapy (NC) Should Be Administered to Fit Patients With Newly Diagnosed, Potentially Resectable Muscle-Invasive Urothelial Cancer (MIUC) of the Bladder – A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process

Canadian Urological Association Journal

Urology

2013

English

2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) Guidelines for the Management of Castration-Resistant Prostate Cancer (CRPC)

Canadian Urological Association Journal

Urology

2019

English

Related publications

Neoadjuvant Chemotherapy Prior to Radical Cystectomy for Muscle-Invasive Bladder Cancer With Variant Histology

English

Should Chemotherapy Still Be Used to Treat All Muscle Invasive Bladder Cancer in the “Era of Immunotherapy”?

Expert Review of Anticancer Therapy

Oncology

Pharmacology

2019

English

Pd15-09 Neoadjuvant vs Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Propensity Matched Analysis

Journal of Urology

Urology

2018

English

Efficient Delivery of Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

English

Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-Confined Muscle-Invasive Bladder Cancer

Urology

2017

English

Amplification of 7p12 Is Associated With Pathologic Non-Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer

American Journal of Pathology

Forensic Medicine

Pathology

2020

English

A Pilot Study- Neoadjuvant Chemotherapy With Gemcitabine and S1 in Patients With Resectable and Borderline Resectable Pancreatic Cancer

Journal of Carcinogenesis & Mutagenesis

2013

English

The Ratio of CD8 to Treg Tumor-Infiltrating Lymphocytes Is Associated With Response to Cisplatin-Based Neoadjuvant Chemotherapy in Patients With Muscle Invasive Urothelial Carcinoma of the Bladder

English

Is BCL-2 a Predictive Marker of Neoadjuvant Chemotherapy Response in Patients With Urothelial Bladder Cancer Undergoing Radical Cystectomy?

Scandinavian Journal of Urology

Urology

Nephrology

2019

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Srikala Sridhar

Neoadjuvant Chemotherapy (NC) Should Be Administered to Fit Patients With Newly Diagnosed, Potentially Resectable Muscle-Invasive Urothelial Cancer (MIUC) of the Bladder – A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process

2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) Guidelines for the Management of Castration-Resistant Prostate Cancer (CRPC)

Related publications

Neoadjuvant Chemotherapy Prior to Radical Cystectomy for Muscle-Invasive Bladder Cancer With Variant Histology

Should Chemotherapy Still Be Used to Treat All Muscle Invasive Bladder Cancer in the “Era of Immunotherapy”?

Pd15-09 Neoadjuvant vs Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Propensity Matched Analysis

Efficient Delivery of Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-Confined Muscle-Invasive Bladder Cancer

Amplification of 7p12 Is Associated With Pathologic Non-Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer

A Pilot Study- Neoadjuvant Chemotherapy With Gemcitabine and S1 in Patients With Resectable and Borderline Resectable Pancreatic Cancer

The Ratio of CD8 to Treg Tumor-Infiltrating Lymphocytes Is Associated With Response to Cisplatin-Based Neoadjuvant Chemotherapy in Patients With Muscle Invasive Urothelial Carcinoma of the Bladder

Is BCL-2 a Predictive Marker of Neoadjuvant Chemotherapy Response in Patients With Urothelial Bladder Cancer Undergoing Radical Cystectomy?